In recent years, wild-type isocitrate dehydrogenase 1 (IDH1) mutation, 1p/19q codeletion, and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation have been widely applied for molecular classification of glioma, but these markers are of limited value for predicting prognosis and response to therapy. The gene discussed is MGMT; the disease is glioma.